New drug HPG1860 shows promise in reducing liver fat in NASH patients

NCT ID NCT05338034

Completed Disease control Sponsor: Hepagene (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested three different doses of HPG1860, an experimental oral drug, against a placebo in 89 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. The main goals were to check safety and see if the drug could lower liver fat content measured by MRI. Results will help determine if larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HPG1860
What this could lead to: If successful, this could point toward a treatment that reduces liver fat in people with NASH, potentially slowing disease progression.
What could go wrong: This is an early Phase 2a trial with only 89 participants. The main focus is safety, and it may not show enough benefit to move forward. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASH - NONALCOHOLIC STEATOHEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASH - NONALCOHOLIC STEATOHEPATITIS

Contacts and locations

Locations

South Texas Research Institute (STRI)

Texas City, Texas, 78240, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.